UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Sie befinden Sich nicht im Netzwerk der Universität Paderborn. Der Zugriff auf elektronische Ressourcen ist gegebenenfalls nur via VPN oder Shibboleth (DFN-AAI) möglich. mehr Informationen...

Median 3.5-Year Follow-up of Ibrutinib Treatment in Patients with Relapsed/Refractory Mantle Cell Lymphoma: A Pooled Analysis

Blood, 2017-12, Vol.130, p.151-151

2017

Link zum Volltext

Verfügbarkeit prüfen

Long-Term Safety Experience with Bendamustine for Injection in a Real-World Setting

Blood, 2016-12, Vol.128 (22), p.5591-5591

2016

Link zum Volltext

Verfügbarkeit prüfen

Evaluation of Eligibility Criteria in First-Line Clinical Trials for Follicular Lymphoma: A MER/LEO Database Analysis

Blood, 2021-11, Vol.138 (Supplement 1), p.338-338

2021

Link zum Volltext

Verfügbarkeit prüfen

The Bruton's Tyrosine Kinase Inhibitor PCI-32765 Is Highly Active As Single-Agent Therapy in Previously-Treated Mantle Cell Lymphoma (MCL): Preliminary Results of a Phase II Trial

Blood, 2011-11, Vol.118 (21), p.442-442

2011

Link zum Volltext

Verfügbarkeit prüfen

Idelalisib is effective in patients with high-risk follicular lymphoma and early relapse after initial chemoimmunotherapy

Blood, 2017-06, Vol.129 (22), p.3037-3039

2017

Link zum Volltext

Verfügbarkeit prüfen

Predictive value of staging PET/CT to detect bone marrow involvement and early outcomes in marginal zone lymphoma

Blood, 2023-04, Vol.141 (15), p.1888-1893

2023

Link zum Volltext

Verfügbarkeit prüfen

Follicular lymphoma: evolving therapeutic strategies

Blood, 2016-04, Vol.127 (17), p.2055-2063

2016

Link zum Volltext

Verfügbarkeit prüfen

FLIPI24: An Improved International Prognostic Model Developed on Early Events in Follicular Lymphoma

BLOOD, 2022-11, Vol.140 (Supplement 1), p.2292-2295

2022

Link zum Volltext

Verfügbarkeit prüfen

Phosphoproteomics Uncovers Synergy between DNA-PK and FLT3 Inhibitors in Acute Myeloid Leukaemia

Blood, 2020-11, Vol.136 (Supplement 1), p.12-12

2020

Link zum Volltext

Verfügbarkeit prüfen

Evaluating the Impact of Lab-Based Eligibility Criteria By Race/Ethnicity in Frontline Clinical Trials for Diffuse Large B-Cell Lymphoma (DLBCL): A LEO Cohort Analysis

Blood, 2022-11, Vol.140 (Supplement 1), p.2056-2058

2022

Link zum Volltext

Verfügbarkeit prüfen

Predictive Value of Staging PET/CT to Detect Bone Marrow Involvement in Marginal Zone Lymphoma (MZL): An Analysis from LEO MZL Working Group

Blood, 2022-11, Vol.140 (Supplement 1), p.9340-9341

2022

Link zum Volltext

Verfügbarkeit prüfen

Development of a Conditional Event-Free Survival Tool in Diffuse Large B-Cell Lymphoma

Blood, 2022-11, Vol.140 (Supplement 1), p.1921-1923

2022

Link zum Volltext

Verfügbarkeit prüfen

Mutations Associated with Progression in Follicular Lymphoma Predict Inferior Outcomes in Newly Diagnosed Patients (Alliance 151303)

Blood, 2022-11, Vol.140 (Supplement 1), p.3543-3545

2022

Link zum Volltext

Verfügbarkeit prüfen

Outcomes and Prognostic Factors of Transformed Follicular Lymphoma: An Analysis from the LEO Consortium

Blood, 2022-11, Vol.140 (Supplement 1), p.6642-6644

2022

Link zum Volltext

Verfügbarkeit prüfen

Long-Term Outcomes with Ibrutinib Versus the Prior Regimen: A Pooled Analysis in Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL) with up to 7.5 Years of Extended Follow-up

Blood, 2019-11, Vol.134 (Supplement_1), p.1538-1538

2019

Link zum Volltext

Verfügbarkeit prüfen

Minimal Residual Disease (MRD) Assessment in the ECOG1411 Randomized Phase 2 Trial of Front-Line Bendamustine-Rituximab (BR)-Based Induction Followed By Rituximab (R) ± Lenalidomide (L) Consolidation for Mantle Cell Lymphoma (MCL)

Blood, 2019-11, Vol.134 (Supplement_1), p.751-751

2019

Link zum Volltext

Verfügbarkeit prüfen

Vulnerable Elders Survey-13 (VES-13) Predicts 1-Year Mortality Risk in Newly Diagnosed Non-Hodgkin Lymphoma (NHL)

Blood, 2019-11, Vol.134 (Supplement_1), p.69-69

2019

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 119

Suche als RSS-Feed

Aktive Filter

Zeitschrift / SerieBlood

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(119)
Mit Volltextzugriff
(117)

Publikationsform

Artikel
(119)

Sprache

Erscheinungsjahr

n.n

Thema

Hematology
(73)
Life Sciences & Biomedicine
(72)
Science & Technology
(72)
Humans
(71)
Male
(35)
Female
(34)
Middle Aged
(33)
Aged
(29)
Adult
(24)
Biochemistry
(24)
Cell Biology
(24)
Immunology
(24)
Biological And Medical Sciences
(18)
Lymphoma, Mantle-Cell - Drug Therapy
(16)
Medical Sciences
(16)
Treatment Outcome
(16)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(15)
Clinical Trials And Observations
(15)
Prognosis
(15)
Antineoplastic Agents - Therapeutic Use
(14)

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

EZB Electronic Journals Library
(119)
Single Journals
(119)

Zeitschrift / Serie

Blood Advances
(1)

Menü

Weitere Dienste

Einstellungen

Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results

Median 3.5-Year Follow-up of Ibrutinib Treatment in Patients with Relapsed/Refractory Mantle Cell Lymphoma: A Pooled Analysis

Long-Term Safety Experience with Bendamustine for Injection in a Real-World Setting

Evaluation of Eligibility Criteria in First-Line Clinical Trials for Follicular Lymphoma: A MER/LEO Database Analysis

The Bruton's Tyrosine Kinase Inhibitor PCI-32765 Is Highly Active As Single-Agent Therapy in Previously-Treated Mantle Cell Lymphoma (MCL): Preliminary Results of a Phase II Trial

Idelalisib is effective in patients with high-risk follicular lymphoma and early relapse after initial chemoimmunotherapy

Predictive value of staging PET/CT to detect bone marrow involvement and early outcomes in marginal zone lymphoma

Follicular lymphoma: evolving therapeutic strategies

FLIPI24: An Improved International Prognostic Model Developed on Early Events in Follicular Lymphoma

Phosphoproteomics Uncovers Synergy between DNA-PK and FLT3 Inhibitors in Acute Myeloid Leukaemia

Consensus recommendations on the management of toxicity associated with CD3×CD20 bispecific antibody therapy

Efficacy and Safety of Zanubrutinib in Patients with Treatment-Naive Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) with Del(17p): Initial Results from Arm C of the Sequoia (BGB-3111-304) Trial

Evaluating the Impact of Lab-Based Eligibility Criteria By Race/Ethnicity in Frontline Clinical Trials for Diffuse Large B-Cell Lymphoma (DLBCL): A LEO Cohort Analysis

Predictive Value of Staging PET/CT to Detect Bone Marrow Involvement in Marginal Zone Lymphoma (MZL): An Analysis from LEO MZL Working Group

Development of a Conditional Event-Free Survival Tool in Diffuse Large B-Cell Lymphoma

Patterns of Care and Clinical Outcomes in Peripheral T-Cell Lymphomas: The Lymphoma Epidemiology of Outcomes (LEO) and Molecular Epidemiology Resource (LEO-MER) Prospective Cohort Study

Mutations Associated with Progression in Follicular Lymphoma Predict Inferior Outcomes in Newly Diagnosed Patients (Alliance 151303)

Outcomes and Prognostic Factors of Transformed Follicular Lymphoma: An Analysis from the LEO Consortium

Randomized Phase 2 Trial of First-Line Bendamustine-Rituximab (BR)-Based Induction Followed By Rituximab (R) ± Lenalidomide (L) Consolidation for Mantle Cell Lymphoma ECOG-ACRIN E1411

Long-Term Outcomes with Ibrutinib Versus the Prior Regimen: A Pooled Analysis in Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL) with up to 7.5 Years of Extended Follow-up

Minimal Residual Disease (MRD) Assessment in the ECOG1411 Randomized Phase 2 Trial of Front-Line Bendamustine-Rituximab (BR)-Based Induction Followed By Rituximab (R) ± Lenalidomide (L) Consolidation for Mantle Cell Lymphoma (MCL)

SEQUOIA: Results of a Phase 3 Randomized Study of Zanubrutinib versus Bendamustine + Rituximab (BR) in Patients with Treatment-Naïve (TN) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

Efficacy and Safety of Zanubrutinib in Patients with Treatment-Naïve (TN) Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) with del(17p): Follow-up Results from Arm C of the SEQUOIA (BGB-3111-304) Trial

Vulnerable Elders Survey-13 (VES-13) Predicts 1-Year Mortality Risk in Newly Diagnosed Non-Hodgkin Lymphoma (NHL)

Utility and Patterns of Use of PET/CT and Bone Marrow Biopsy for Staging in Non-Hodgkin Lymphoma in the Clinical Setting: A Retrospective Analysis Using the LEO Database

Aktive Filter

Suchergebnisse filtern